Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could provide a notable advancement for weight loss . Early clinical trials https://getretatrutideaustralia.com/blog/retatrutide-results-side-effects-cost